Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Sanofi - American Depositary Shares
(NQ:
SNY
)
48.37
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi - American Depositary Shares
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
40
41
Next >
Biotech Breakout: Stocks for Your Watchlist
September 12, 2024
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150.
Via
MarketBeat
Topics
ETFs
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
↗
September 11, 2024
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints.
Via
Benzinga
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
September 11, 2024
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Despite its impressive fundamentals, NASDAQ:SNY remains undervalued.
↗
September 10, 2024
When you look at SANOFI-ADR (NASDAQ:SNY), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via
Chartmill
NASDAQ:SNY may be ready to breakout.
↗
August 12, 2024
Will SANOFI-ADR breakout?
Via
Chartmill
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
↗
September 06, 2024
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.
Via
Benzinga
Why Sanofi Stock Was Robustly Healthy Today
↗
September 03, 2024
Investors found something to like about the company's recent round of clinical trials for a key pipeline medication.
Via
The Motley Fool
Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials
↗
September 03, 2024
Sanofi's phase 3 HERCULES study data shows tolebrutinib met the primary endpoint in delaying disability progression in non-relapsing secondary progressive multiple sclerosis.
Via
Benzinga
European Stocks Little Moved On Labor Day, German DAX Mark Record Close, Natural Gas Futures Rise: What's Driving Markets Monday?
↗
September 02, 2024
Global markets started September cautiously, with thin trading volumes as U.S. stock markets were closed for the Labor Day holiday.
Via
Benzinga
Topics
Energy
Governments Suing Pharmacy Benefit Managers Over Insulin Prices Have Long Benefited From Their Rebates
↗
August 26, 2024
State and local governments suing PBMs and drug companies over insulin prices have long benefited from the same rebate system they now criticize, leaving patients burdened by high costs and limited...
Via
Benzinga
Wall Street Predicts That This Stock Could Skyrocket by 65%: Time to Buy?
↗
August 24, 2024
Don't be too quick to jump on the Wall Street bandwagon.
Via
The Motley Fool
ARS Pharmaceuticals 'Neffy Uniquely Positioned With Potential To Change Allergy Treatment Paradigm For First Time In 40 years:' Analyst
↗
August 20, 2024
"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and...
Via
Benzinga
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
↗
August 19, 2024
Its 12-month relative strength performance is impressive, but Novavax now faces resistance.
Via
Investor's Business Daily
NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.
↗
August 19, 2024
SANOFI-ADR (NASDAQ:SNY) appears to be flying under the radar despite its strong fundamentals.
Via
Chartmill
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
↗
August 16, 2024
A Florida State Court sided with GSK, dismissing expert testimonies that linked ranitidine to prostate cancer, reflecting a broader scientific consensus that there is no consistent evidence supporting...
Via
Benzinga
3 Biotech Stocks to Buy on the Dip: August 2024
↗
August 15, 2024
These are three of the best biotech stocks to buy on the dip due to their strong fundamentals and market positioning.
Via
InvestorPlace
AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering
↗
August 14, 2024
The company is working on treatments for immunological diseases, including eczema and rheumatoid arthritis.
Via
Investor's Business Daily
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
August 12, 2024
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases.
Via
MarketBeat
FDA Approves ARS Pharma's Once Rejected Neffy Nasal Spray Alternative To EpiPen For Emergency Allergy Treatment
↗
August 09, 2024
FDA approves ARS Pharmaceuticals' Neffy, the first nasal spray for treating severe allergic reactions and anaphylaxis. This new option offers a non-injection alternative to epinephrine autoinjectors,...
Via
Benzinga
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
August 08, 2024
Via
Investor Brand Network
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit
↗
August 08, 2024
Novavax reported Q2 2024 revenue of $415 million, missing estimates, with net income rising to $162 million. EPS increased to $0.99, below expectations. The company revised its 2024 revenue guidance to...
Via
Benzinga
Sanofi's Approved Blood Cancer Drug Sarclisa Shows Improved Progression-Free Survival In Patients Eligible For Transplant
↗
August 08, 2024
Sanofi's phase 3 GMMG-HD7 study reveals that Sarclisa, combined with lenalidomide, bortezomib, and dexamethasone, significantly prolongs progression-free survival in newly diagnosed multiple myeloma...
Via
Benzinga
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END
Via
FinancialNewsMedia
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Where Will Novavax Be in 5 Years?
↗
August 03, 2024
Its been a good year so far for the biotech, but how long can it keep the momentum going?
Via
The Motley Fool
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
↗
August 01, 2024
Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD, Dupixent, and Libtayo. Notable: 18% decline in Eylea US sales; 42%...
Via
Benzinga
JPMorgan Just Cut Its Price Target on These 3 Stocks: July 31, 2024
↗
July 31, 2024
Analysts from JPMorgan Chase have expressed their concern about the outlook for these stocks with lowered price targets.
Via
InvestorPlace
JPMorgan Just Issued a Warning on Novavax (NVAX) Stock
↗
July 30, 2024
Novavax has inked a key vaccine deal with Sanofi, but NVAX stock is down after JPMorgan warned about overvaluation concerns.
Via
InvestorPlace
Sanofi (SNY) Q2 2024 Earnings Call Transcript
↗
July 25, 2024
SNY earnings call for the period ending June 30, 2024.
Via
The Motley Fool
Topics
Earnings
Stocks Rebound As US Economy Flexes Muscles, Small Caps Rally, Gold Falls: What's Driving Markets Thursday?
↗
July 25, 2024
Wall Street strongly rebounded Thursday after Wednesday’s slump, driven by stronger-than-expected economic growth in the last quarter, countering concerns of a slowdown.
Via
Benzinga
Topics
Economy
< Previous
1
2
...
7
8
9
10
11
12
13
14
15
...
40
41
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
